The Art of Finding the Right Drug Target: Emerging Methods and Strategies
Pharmacological Reviews,
Год журнала:
2024,
Номер
76(5), С. 896 - 914
Опубликована: Июнь 12, 2024
Drug
targets
are
specific
molecules
in
biological
tissues
and
body
fluids
that
interact
with
drugs.
target
discovery
is
a
key
component
of
drug
essential
for
the
development
new
drugs
areas
such
as
cancer
therapy
precision
medicine.
Traditional
in
vitro
or
vivo
methods
time-consuming
labour-intensive,
limiting
pace
discovery.
With
modern
methods,
application
various
emerging
technologies
have
greatly
improved
efficiency
discovery,
shortened
cycle
time
reduced
cost.
This
review
provides
comprehensive
overview
strategies,
including
computer-assisted
approaches,
affinity
response
stability,
multiomics
analysis,
gene
editing,
NMD,
discusses
effectiveness
limitations
well
their
real
cases.
Through
above
related
contents,
general
novel
disease
treatment
strategies
will
be
provided,
theoretical
basis
provided
those
who
engaged
pharmaceutical
science
research.
Significance
Statement
Target-based
has
been
main
approach
to
industry
past
three
decades.
based
on
or
validation
costly,
Therefore,
selection
process
crucial.
Язык: Английский
Exploring the Role of HtrA Family Genes in Cancer: A Systematic Review
Molecular Diagnosis & Therapy,
Год журнала:
2024,
Номер
28(4), С. 347 - 377
Опубликована: Май 8, 2024
HtrA1,
HtrA2,
HtrA3
and
HtrA4
appear
to
be
involved
in
the
development
of
pathologies
such
as
cancer.
This
systematic
review
reports
results
a
literature
search
performed
compare
expression
HtrA
family
genes
proteins
cancer
versus
non-cancer
tissues
cell
lines,
assess
relationships
between
clinical
features
cancer,
analyse
molecular
mechanism,
by
which
affects
The
was
conducted
according
PRISMA
statement
among
four
databases
(PubMed,
Web
Science,
Embase
Scopus).
A
total
38
articles
met
inclusion
criteria
members
concerned
effect
on
metastasis
or
factor
that
influences
it.
Additionally,
31
were
retrieved
manually.
Most
highlighted
HtrA1
exhibited
tumour
suppressor
activity,
while
HtrA2
associated
with
growth
metastasis.
There
too
few
studies
clearly
define
role
protease
tumours.
Although
serine
proteases
dependent
type,
stage
presence
metastases,
most
indicated
tumours
downregulated
compared
healthy
tissue
lines.
completely
study
dependent.
limited
number
made
it
impossible
draw
conclusions
about
differences
tissue.
drawn
from
suggest
act
suppressors.
Язык: Английский
SCGB1A1 as a novel biomarker and promising therapeutic target for the management of HNSCC
Oncology Letters,
Год журнала:
2024,
Номер
28(5)
Опубликована: Сен. 3, 2024
Head
and
neck
cancer
(HNC)
is
the
sixth
most
common
type
of
worldwide,
head
squamous
cell
carcinoma
(HNSCC)
accounts
for
90%
HNC
cases.
Furthermore,
HNSCC
400,000
cancer‑associated
deaths
worldwide
each
year.
However,
at
present
there
an
absence
a
versatile
biomarker
that
can
be
used
diagnosis,
prognosis
evaluation
as
therapeutic
target
HNSCC.
In
study,
bioinformatics
analysis
was
to
assess
relationship
between
hub
genes
clinical
features
patients
with
The
findings
from
were
then
verified
using
samples
in
vitro
experiments.
A
total
51
overlapping
identified
intersection
differentially
expressed
co‑expressed
genes.
top
10
obtained
protein‑protein
interaction
network
Among
genes,
only
secretoglobin
family
1A
member
1
(SCGB1A1)
significantly
associated
both
overall
disease‑free
survival.
Specifically,
upregulated
SCGB1A1
expression
levels
prolonged
Moreover,
negatively
correlated
drug
sensitivity.
Notably,
it
demonstrated
SCGB1A1
involved
in
tumor
immunoreaction
by
affecting
infiltration
cells
checkpoint
regulation
immune
cells.
Additionally,
shown
regulated
multiple
key
cancer‑related
signaling
pathways,
including
extracellular
matrix
receptor
interaction,
transforming
growth
factor‑β
metabolism
pathways.
Based
on
results
may
serve
novel
predicting
effectiveness
certain
drugs
potential
management
Язык: Английский